Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 31-Oct-18 4:04 PM View:  | Baupost Group Llc/ma 10% Owner | Orexigen Therapeutics, Inc. (OREXQ) | 31-Oct-18 | Sale | 896,339 | $0.01 | $8,963.39 | (100%) 896.34K to 0 | |
| 31-Oct-18 4:04 PM View: | Baupost Group Llc/ma 10% Owner | Orexigen Therapeutics, Inc. (OREXQ) | 29-Oct-18 | Sale | 650,000 | $0.01 | $6,500.00 | (42%) 1.55M to 896.34K | |
| 26-Oct-18 4:12 PM View: | Baupost Group Llc/ma 10% Owner | Orexigen Therapeutics, Inc. (OREXQ) | 25-Oct-18 | Sale | 652,500 | $0.01 | $6,525.00 | (30%) 2.2M to 1.55M | |
| 26-Oct-18 4:12 PM View: | Baupost Group Llc/ma 10% Owner | Orexigen Therapeutics, Inc. (OREXQ) | 24-Oct-18 | Sale | 28,000 | $0.01 | $280.00 | (1%) 2.23M to 2.2M | |
| 16-Mar-18 4:20 PM View: | Moglia Stephen A. VP & Chief Accounting Officer | Orexigen Therapeutics, Inc. (OREXQ) | 15-Mar-18 | Sale | 1,694 | $0.24 | $406.56 | (100%) 1.69K to 0 | |
| 02-Jun-17 4:47 PM View: | Lynch Thomas P. EVP. General Counsel & Sec. | Orexigen Therapeutics, Inc. (OREXQ) | 31-May-17 | Grant | 1,704 | $1.55 | $2,641.20 | 100% 0 to 1.7K | |
| 02-Jun-17 4:33 PM View: | Cannell Thomas R EVP, COO, Pres Global Com Prod | Orexigen Therapeutics, Inc. (OREXQ) | 31-May-17 | Grant | 2,119 | $1.55 | $3,284.45 | 120% 1.76K to 3.88K | |
| 02-Jun-17 4:55 PM View: | Narachi Michael CEO & President Director | Orexigen Therapeutics, Inc. (OREXQ) | 31-May-17 | Grant | 626 | $1.55 | $970.30 | 8% 7.73K to 8.36K | |
| 02-Jun-17 4:44 PM View: | Keyes Jason A SVP, Chief Financial Officer | Orexigen Therapeutics, Inc. (OREXQ) | 31-May-17 | Grant | 557 | $1.55 | $863.35 | 23% 2.47K to 3.03K | |
| 21-Dec-16 12:11 PM View: | Moglia Stephen A. VP, Chief Accounting Officer | Orexigen Therapeutics, Inc. (OREXQ) | 19-Dec-16 | Market Sale | 800 | $1.96 | $1,568.00 | (100%) 0.8K to 0 | (64%) |
| 02-Dec-16 5:09 PM View: | Cannell Thomas R EVP, COO, Pres Global Com Prod | Orexigen Therapeutics, Inc. (OREXQ) | 30-Nov-16 | Grant | 291 | $1.67 | $485.97 | 20% 1.47K to 1.76K | |
| 02-Dec-16 5:11 PM View: | Narachi Michael CEO & President Director | Orexigen Therapeutics, Inc. (OREXQ) | 30-Nov-16 | Grant | 802 | $1.67 | $1,339.34 | 15% 5.51K to 6.31K | |
| 02-Dec-16 5:10 PM View: | Keyes Jason A SVP, Chief Financial Officer | Orexigen Therapeutics, Inc. (OREXQ) | 30-Nov-16 | Grant | 291 | $1.67 | $485.97 | 13% 2.18K to 2.47K | |
| 02-Jun-16 11:23 AM View: | Narachi Michael CEO & President Director | Orexigen Therapeutics, Inc. (OREXQ) | 31-May-16 | Grant | 8,777 | $0.34 | $2,984.18 | 15% 60.51K to 69.28K | |
| 02-Jun-16 11:22 AM View: | Cannell Thomas R EVP, Chief Commercial Officer | Orexigen Therapeutics, Inc. (OREXQ) | 31-May-16 | Grant | 9,632 | $0.34 | $3,274.88 | 189% 5.09K to 14.72K | |
| 04-Feb-16 12:06 PM View: | Klassen Preston EVP, Global Development | Orexigen Therapeutics, Inc. (OREXQ) | 30-Nov-15 | Grant | 4,170 | $2.03 | $8,465.10 | 70% 5.99K to 10.16K | |
| 04-Feb-16 12:04 PM View: | Narachi Michael CEO & President Director | Orexigen Therapeutics, Inc. (OREXQ) | 30-Nov-15 | Grant | 1,761 | $2.03 | $3,574.83 | 3% 58.75K to 60.51K | |
| 04-Feb-16 12:06 PM View: | Cannell Thomas R EVP, Chief Commercial Officer | Orexigen Therapeutics, Inc. (OREXQ) | 30-Nov-15 | Grant | 5,091 | $2.03 | $10,334.70 | 100% 0 to 5.09K | |
| 04-Feb-16 12:06 PM View: | Klassen Preston EVP, Global Development | Orexigen Therapeutics, Inc. (OREXQ) | 30-May-15 | Grant | 1,860 | $4.17 | $7,756.20 | 45% 4.13K to 5.99K | |
| 04-Feb-16 12:04 PM View: | Narachi Michael CEO & President Director | Orexigen Therapeutics, Inc. (OREXQ) | 29-May-15 | Grant | 721 | $4.17 | $3,006.57 | 1% 58.03K to 58.75K | |
| 02-Mar-15 5:34 PM View: | Booth Mark D Chief Commercial Officer | Orexigen Therapeutics, Inc. (OREXQ) | 26-Feb-15 | Market Option Sale (Planned) | 50,000 | $5.68 | $284,200.00 | (93%) 53.81K to 3.81K | 94% |
| 02-Mar-15 5:34 PM View: | Booth Mark D Chief Commercial Officer | Orexigen Therapeutics, Inc. (OREXQ) | 26-Feb-15 | Option Exercise | 50,000 | $1.66 | $83,000.00 | 1312% 3.81K to 53.81K | |
| 04-Dec-14 5:05 PM View: | Turner Heather D SVP, Gen. Counsel & Secretary | Orexigen Therapeutics, Inc. (OREXQ) | 02-Dec-14 | Option Exercise | 22,643 | $1.66 | $37,587.40 | 100% 0 to 22.64K | |
| 04-Dec-14 5:05 PM View: | Turner Heather D SVP, Gen. Counsel & Secretary | Orexigen Therapeutics, Inc. (OREXQ) | 02-Dec-14 | Market Option Sale (Planned) | 22,643 | $6.00 | $135,858.00 | (100%) 22.64K to 0 | 95% |
| 05-Feb-15 5:32 PM View: | Klassen Preston SVP, Head Global Development | Orexigen Therapeutics, Inc. (OREXQ) | 28-Nov-14 | Grant | 1,542 | $4.92 | $7,586.64 | 60% 2.59K to 4.13K | |
| 26-Nov-14 5:01 PM View: | Turner Heather D SVP, Gen. Counsel & Secretary | Orexigen Therapeutics, Inc. (OREXQ) | 25-Nov-14 | Option Exercise | 7,382 | $1.66 | $12,254.10 | 100% 0 to 7.38K | |
| 26-Nov-14 5:01 PM View: | Turner Heather D SVP, Gen. Counsel & Secretary | Orexigen Therapeutics, Inc. (OREXQ) | 25-Nov-14 | Market Option Sale (Planned) | 7,382 | $6.00 | $44,292.00 | (100%) 7.38K to 0 | 95% |
| 26-Nov-14 5:01 PM View: | Turner Heather D SVP, Gen. Counsel & Secretary | Orexigen Therapeutics, Inc. (OREXQ) | 24-Nov-14 | Option Exercise | 24,006 | $1.66 | $39,850.00 | 100% 0 to 24.01K | |
| 26-Nov-14 5:01 PM View: | Turner Heather D SVP, Gen. Counsel & Secretary | Orexigen Therapeutics, Inc. (OREXQ) | 24-Nov-14 | Market Option Sale (Planned) | 24,006 | $5.77 | $138,587.00 | (100%) 24.01K to 0 | 94% |
| 20-Nov-14 9:16 AM View: | Bock Louis C Director | Orexigen Therapeutics, Inc. (OREXQ) | 18-Nov-14 | Market Purchase | 625 | $5.58 | $3,486.88 | 2% 27.05K to 27.68K | (94%) |
| 20-Nov-14 9:16 AM View: | Bock Louis C Director | Orexigen Therapeutics, Inc. (OREXQ) | 18-Nov-14 | Market Purchase | 700 | $5.58 | $3,905.30 | 3% 27.68K to 28.38K | (94%) |
| 13-Nov-14 9:27 AM View: | Bock Louis C Director | Orexigen Therapeutics, Inc. (OREXQ) | 12-Nov-14 | Market Purchase | 27,052 | $5.57 | $150,544.00 | 100% 0 to 27.05K | (94%) |
| 22-Sep-14 6:49 PM View: | Turner Heather D VP, Gen. Counsel & Secretary | Orexigen Therapeutics, Inc. (OREXQ) | 22-Sep-14 | Option Exercise | 300,000 | $1.66 | $498,000.00 | 100% 0 to 300.0K | |
| 22-Sep-14 6:49 PM View: | Turner Heather D VP, Gen. Counsel & Secretary | Orexigen Therapeutics, Inc. (OREXQ) | 22-Sep-14 | Market Option Sale | 300,000 | $4.47 | $1,339,500.00 | (100%) 300.0K to 0 | 93% |
| 15-Sep-14 3:11 PM View: | Hagan Joseph P Sr. VP, Corporate Development | Orexigen Therapeutics, Inc. (OREXQ) | 15-Sep-14 | Market Purchase | 5,000 | $4.69 | $23,450.00 | 62% 8.03K to 13.03K | (93%) |
| 15-Sep-14 2:41 PM View: | Narachi Michael President and CEO Director | Orexigen Therapeutics, Inc. (OREXQ) | 15-Sep-14 | Market Purchase | 50,000 | $4.78 | $239,100.00 | 623% 8.03K to 58.03K | (93%) |
| 05-Feb-15 5:32 PM View: | Klassen Preston SVP, Head Global Development | Orexigen Therapeutics, Inc. (OREXQ) | 30-May-14 | Grant | 1,318 | $5.25 | $6,919.50 | 104% 1.27K to 2.59K | |
| 05-Feb-15 5:33 PM View: | Booth Mark D Chief Commercial Officer | Orexigen Therapeutics, Inc. (OREXQ) | 30-May-14 | Grant | 4,218 | $5.25 | $22,144.50 | 111% 3.81K to 8.03K | |
| 23-Apr-14 5:15 PM View: | Dovey Brian H Director | Orexigen Therapeutics, Inc. (OREXQ) | 22-Apr-14 | Payment of Exercise | 886 | $5.30 | $4,695.80 | (< 1%) 7.71M to 7.71M | 94% |
| 23-Apr-14 5:15 PM View: | Dovey Brian H Director | Orexigen Therapeutics, Inc. (OREXQ) | 22-Apr-14 | Option Exercise | 4,691,470 | $0.00 | $4,691.47 | 155% 3.02M to 7.71M | |
| 11-Feb-14 7:33 AM View: | Hagan Joseph P Chief Business Officer | Orexigen Therapeutics, Inc. (OREXQ) | 29-Nov-13 | Grant | 3,980 | $5.34 | $21,253.20 | 100% 0 to 3.98K | |
| 11-Feb-14 7:33 AM View: | Turner Heather D VP, Gen. Counsel & Secretary | Orexigen Therapeutics, Inc. (OREXQ) | 29-Nov-13 | Grant | 3,980 | $5.34 | $21,253.20 | 100% 0 to 3.98K | |
| 11-Feb-14 7:32 AM View: | Narachi Michael President and CEO Director | Orexigen Therapeutics, Inc. (OREXQ) | 29-Nov-13 | Grant | 3,980 | $5.34 | $21,253.20 | 100% 0 to 3.98K | |
| 11-Feb-14 7:32 AM View: | Booth Mark D Chief Commercial Officer | Orexigen Therapeutics, Inc. (OREXQ) | 29-Nov-13 | Grant | 3,810 | $5.34 | $20,345.40 | 100% 0 to 3.81K | |
| 11-Feb-14 7:33 AM View: | Klassen Preston SVP, Head Global Development | Orexigen Therapeutics, Inc. (OREXQ) | 29-Nov-13 | Grant | 1,270 | $5.34 | $6,781.80 | 100% 0 to 1.27K | |
| 02-Aug-13 7:34 PM View: | Hagan Joseph P Chief Business Officer | Orexigen Therapeutics, Inc. (OREXQ) | 31-Jul-13 | Option Exercise | 12,000 | $1.66 | $19,920.00 | 100% 0 to 12.0K | |
| 02-Aug-13 7:34 PM View: | Hagan Joseph P Chief Business Officer | Orexigen Therapeutics, Inc. (OREXQ) | 31-Jul-13 | Market Option Sale (Planned) | 12,000 | $7.80 | $93,600.00 | (100%) 12.0K to 0 | 96% |
| 29-Jul-13 7:49 PM View: | Hagan Joseph P Chief Business Officer | Orexigen Therapeutics, Inc. (OREXQ) | 26-Jul-13 | Option Exercise | 10,000 | $1.66 | $16,600.00 | 100% 0 to 10.0K | |
| 29-Jul-13 7:50 PM View: | Booth Mark D Chief Commercial Officer | Orexigen Therapeutics, Inc. (OREXQ) | 26-Jul-13 | Option Exercise | 64,767 | $1.66 | $107,513.00 | 100% 0 to 64.77K | |
| 29-Jul-13 7:49 PM View: | Hagan Joseph P Chief Business Officer | Orexigen Therapeutics, Inc. (OREXQ) | 26-Jul-13 | Market Option Sale (Planned) | 10,000 | $7.40 | $74,000.00 | (100%) 10.0K to 0 | 96% |
